Biologic Therapy and Treatment Options in Diabetic Retinopathy with Diabetic Macular Edema

Tobias    P. H.    Nissen; Henrik       Vorum; Kristian       Aasbjerg
doi:10.2174/1574886315666200902154322
Abstract

Proliferative diabetic retinopathy and diabetic macular edema can be a potentially sightthreatening disease if not treated correctly. It is directly correlated to the duration of diabetes and how well managed the patients' diabetes is. In the last 15 years, the treatment of diabetic eye disease has taken a quantum leap in methodology due to the group of biological agents named antivascular endothelial growth factor (anti-VEGF). The introduction of the first biological agent has revolutionized the treatment, not only in diabetic eye disease but also across most inflammatory eye diseases, causing leakage of fluid from the blood vessels i.e., in age-related macular degeneration. The availability of these biological agents, despite their considerable costs, have significantly improved the outcomes measured in visual acuity compared to more traditional treatments of diabetic retinopathy in the form of sole laser treatment and glycemic control. The agents demonstrate a favorable safety profile, but if the rarest and most severe side effects occur, there is a potential total loss of vision.
This review aims to make an overview of the current pharmaceutical therapeutic options in the treatment of diabetic macular edema. This includes laser therapy, intravitreal steroids, and a primary focus on intravitreal antivascular endothelial growth factors.
Keywords: Diabetic macular edema, anti-VEGF, laser, corticosteroids, safety profile, treatment.
« Previous Next »
[1] 
Korsgren S, Molin Y, Salmela K, Lundgren T, Melhus A, Korsgren O. On the etiology of type 1 diabetes: A new animal model signifying a decisive role for bacteria eliciting an adverse innate immunity response. Am J Pathol  2012; 181(5): 1735-48.
[http://dx.doi.org/10.1016/j.ajpath.2012.07.022] [PMID: 22944599] 
[2] 
van Belle TL, Coppieters KT, von Herrath MG. Type 1 diabetes: Etiology, immunology, and therapeutic strategies. Physiol Rev  2011; 91(1): 79-118.
[http://dx.doi.org/10.1152/physrev.00003.2010] [PMID: 21248163] 
[3] 
Todd JA. Etiology of Type 1 Diabetes Vol 32, Immunity.  Cell Press 2010; pp. 457-67.
[4] 
Ackland P, Resnikoff S, Bourne R. World blindness and visual impairment: Despite many successes, the problem is growingVol 30, Community Eye Health Journal.  International Centre for Eye Health 2018; pp. 71-3.
[5] 
Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond)  2015; 2(1): 17.
[http://dx.doi.org/10.1186/s40662-015-0026-2] [PMID: 26605370] 
[6] 
Yau JWY, Rogers SL, Kawasaki R, et al. Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care  2012; 35(3): 556-64.
[http://dx.doi.org/10.2337/dc11-1909] [PMID: 22301125] 
[7] 
Guidelines ICO, Care E, Wong T-Y, Aiello LP, Ferris FL, Gupta N, et al. ICO Guidelines for Diabetic Eye Car 2017.www.icoph.org/downloads/icoethicalcode.pdf
[8] 
Ting DSW, Cheung GCM, Wong TY. Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: A review.Vol 44, Clinical and Experimental Ophthalmology.  Blackwell Publishing 2016; pp. 260-77.
[http://dx.doi.org/10.1111/ceo.12696] 
[9] 
Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus - Present and future perspectives. Vol. 8. Nat Rev Endocrinol  2012; 228-36.
[http://dx.doi.org/10.1038/nrendo.2011.183] 
[10] 
Lind M, Pivodic A, Svensson A-M, Ólafsdóttir AF, Wedel H, Ludvigsson J. HbA1c level as a risk factor for retinopathy and nephropathy in children and adults with type 1 diabetes: Swedish population based cohort study. BMJ  2019; 366: l4894.
[http://dx.doi.org/10.1136/bmj.l4894] [PMID: 31462492] 
[11] 
Flaxman SR, Bourne RRA, Resnikoff S, Ackland P, Braithwaite T, Cicinelli MV, et al. Articles Global causes of blindness and distance vision impairment 1990-2020: A systematic review and meta-analysis 2017.www.thelancet.com/lancetgh
[12] 
Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy:  A systematic review JAM Sci  2007; 298: 902-16.
[http://dx.doi.org/10.1001/jama.298.8.902] 
[13] 
Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet  2010; 376(9735): 124-36. [Internet].
[http://dx.doi.org/10.1016/S0140-6736(09)62124-3] [PMID: 20580421] 
[14] 
Leal EC, Manivannan A, Hosoya K-I, Terasaki T, Cunha-Vaz J, Ambrósio AF, et al. Inducible nitric oxide synthase isoform is a key mediator of leukostasis and blood-retinal barrier breakdown in diabetic retinopathy Invest Ophthalmol Vis Sci  2007; 48(11): 5257-65.http://www.ncbi.nlm.nih.gov/pubmed/17962481
[http://dx.doi.org/10.1167/iovs.07-0112] 
[15] 
Wu L, Fernandez-Loaiza P, Sauma J, Hernandez-Bogantes E, Masis M, Hernan-Dez-Bogantes E. Classification of diabetic retinopathy and diabetic macular edema. World J Diabetes  2013; 4(6): 290-4.
[http://dx.doi.org/10.4239/wjd.v4.i6.290] [PMID: 24379919] 
[16] 
Mehlsen J, Erlandsen M, Poulsen PL, Bek T. Identification of independent risk factors for the development of diabetic retinopathy requiring treatment Acta Ophthalmol  2011; 89(6): 515-21.http://doi.wiley.com/10.1111/j.1755-3768.2009.01742.x
[http://dx.doi.org/10.1111/j.1755-3768.2009.01742.x] 
[17] 
Aasbjerg K, Nørgaard CH, Vestergaard N, et al. Risk of diabetes among related and unrelated family members. Diabetes Res Clin Pract  2020; 160107997
[http://dx.doi.org/10.1016/j.diabres.2019.107997] [PMID: 31901471] 
[18] 
Weires MB, Tausch B, Haug PJ, Edwards CQ, Wetter T, Cannon-Albright LA. Familiality of diabetes mellitus. Exp Clin Endocrinol Diabetes  2007; 115(10): 634-40.
[http://dx.doi.org/10.1055/s-2007-984443] [PMID: 18058597] 
[19] 
IDF (International Diabetes Federation). IDF DIABETES ATLAS Eighth edition 2017 (updated march 2020)IDF Diabetes Atlas, 8th edition.   2017; pp. 1-150.
[20] 
Rangel ÉB, Rodrigues CO, De Sá JR. Micro- and Macrovascular Complications in Diabetes Mellitus: Preclinical and Clinical Studies Journal of Diabetes Research 2019.
[21] 
Zimmet PZ. Diabetes and its drivers: The largest epidemic in human history?.  Clinical Diabetes and Endocrinology. BioMed Central Ltd. 2017; Vol. 3.
[22] 
Marshall SM, Flyvbjerg A. Prevention and early detection of vascular complications of diabetes. BMJ  2006; 333(7566): 475-80.
[http://dx.doi.org/10.1136/bmj.38922.650521.80] [PMID: 16946335] 
[23] 
Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: A systematic literature review of scientific evidence from across the world in 2007-2017.  Cardiovascular Diabetology. BioMed Central Ltd. 2018; Vol. 17: pp. 1-19.
[24] 
Marshall SM, Flyvbjerg A. Clinical Review the Prevention and Early Detection of the Vascular Complications of Diabetes BMJ  2006; 333(7566): 475-80.
[25] 
Edema PFDM. Photocoagulation for diabetic macular edema. early treatment diabetic retinopathy study report number 1. early treatment diabetic retinopathy study research group. Arch Ophthalmol  1985; 103(12): 1796-806.
[http://dx.doi.org/10.1001/archopht.1985.01050120030015] [PMID: 2866759] 
[26] 
INTERNATIONAL CLINICAL DIABETIC RETINOPATHY DISEASE SEVERITY SCALE 2002.http://www.icoph.org/downloads/Diabetic-Retinopathy-Scale.pdf
[27] 
Brown DM, Nguyen QD, Marcus DM, et al. RIDE and RISE Research Group. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology  2013; 120(10): 2013-22.
[http://dx.doi.org/10.1016/j.ophtha.2013.02.034] [PMID: 23706949] 
[28] 
Heier JS, Korobelnik JF, Brown DM, Schmidt-Erfurth U, Do DV, Midena E, et al. Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies.Ophthalmology.  Elsevier Inc. 2016; pp. 2376-85.
[29] 
FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125085s323lbl.pdf
[30] 
Varma R, Bressler NM, Doan QV, et al. Prevalence of and risk factors for diabetic macular edema in the United States. JAMA Ophthalmol  2014; 132(11): 1334-40.
[http://dx.doi.org/10.1001/jamaophthalmol.2014.2854] [PMID: 25125075] 
[31] 
Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology  1984; 91(12): 1464-74.
[http://dx.doi.org/10.1016/S0161-6420(84)34102-1] [PMID: 6521986] 
[32] 
Lu L, Jiang Y, Jaganathan R, Hao Y. Current Advances in Pharmacotherapy and Technology for Diabetic Retinopathy: A Systematic Review. J Ophthalmol 2018.
[33] 
Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs- an extension of the modified Airlie House classification. ETDRS report number 10. Ophthalmology  1991; 98(5)(Suppl.): 786-806.
[http://dx.doi.org/10.1016/S0161-6420(13)38012-9] [PMID: 2062513] 
[34] 
Barchetta I, Riccieri V, Vasile M, Stefanantoni K, Comberiati P, Taverniti L, et al. High prevalence of capillary abnormalities in patients with diabetes and association with retinopathy Diabet Med  2011; 28(9): 1039-44.http://www.ncbi.nlm.nih.gov/pubmed/21517956
[http://dx.doi.org/10.1111/j.1464-5491.2011.03325.x] 
[35] 
Wu M, Chen Y, Wilson K, et al. Intraretinal leakage and oxidation of LDL in diabetic retinopathy. Invest Ophthalmol Vis Sci  2008; 49(6): 2679-85.
[http://dx.doi.org/10.1167/iovs.07-1440] [PMID: 18362112] 
[36] 
Ferris FL III, Patz A. Macular edema. A complication of diabetic retinopathy. Surv Ophthalmol  1984; 28: 452-61.
[http://dx.doi.org/10.1016/0039-6257(84)90227-3] [PMID: 6379946] 
[37] 
Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Ophthalmology  1987; 94(7): 761-74.
[http://dx.doi.org/10.1016/S0161-6420(87)33527-4] [PMID: 3658348] 
[38] 
Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology  1991; 98(5)(Suppl.): 766-85.
[http://dx.doi.org/10.1016/S0161-6420(13)38011-7] [PMID: 2062512] 
[39] 
Shrestha GS, Kaiti R. Visual functions and disability in diabetic retinopathy patients. J Optom  2014; 7(1): 37-43.
[http://dx.doi.org/10.1016/j.optom.2013.03.003] [PMID: 24646899] 
[40] 
Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Cochrane Database Syst Rev  2018; 10(10)CD007419
[http://dx.doi.org/10.1002/14651858.CD007419.pub6] [PMID: 30325017] 
[41] 
DrugBank https://www.drugbank.ca/
[42] 
Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table Indiana University School of Medicine 2007.https://drug-interactions.medicine.iu.edu/
[43] 
Holmes K, Roberts OL, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibition. Cell Signal  2007; 19(10): 2003-12.
[http://dx.doi.org/10.1016/j.cellsig.2007.05.013] [PMID: 17658244] 
[44] 
Yamazaki Y, Morita T. Molecular and functional diversity of vascular endothelial growth factors. Mol Divers  2006; 10(4): 515-27.
[http://dx.doi.org/10.1007/s11030-006-9027-3] [PMID: 16972015] 
[45] 
Duffy AM, Bouchier-Hayes DJ, Harmey JH. Vascular Endothelial Growth Factor (VEGF) and Its Role in Non-Endothelial Cells: Autocrine Signalling by VEGF 2013.
[46] 
Al-Halafi AM. Vascular endothelial growth factor trap-eye and trap technology: Aflibercept from bench to bedsid Vol 7, Oman Journal of Ophthalmology  2014; 112-5.
[47] 
Eichmann A, Corbel C, Nataf V, Vaigot P, Bréant C, Le Douarin NM. Ligand-dependent development of the endothelial and hemopoietic lineages from embryonic mesodermal cells expressing vascular endothelial growth factor receptor 2. Proc Natl Acad Sci USA  1997; 94(10): 5141-6.
[http://dx.doi.org/10.1073/pnas.94.10.5141] [PMID: 9144204] 
[48] 
Gerber HP, McMurtrey A, Kowalski J, et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem  1998; 273(46): 30336-43.
[http://dx.doi.org/10.1074/jbc.273.46.30336] [PMID: 9804796] 
[49] 
Connolly DT, Heuvelman DM, Nelson R, et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest  1989; 84(5): 1470-8.
[http://dx.doi.org/10.1172/JCI114322] [PMID: 2478587] 
[50] 
Rahimi N. VEGFR-1 and VEGFR-2: Two non-identical twins with a unique physiognomy.  Frontiers in Bioscience. NIH Public Access 2006; Vol. 11: pp. 818-29.
[51] 
Breen EC. VEGF in biological control Vol 102, Journal of Cellular Biochemistry  2007; 1358-67.http://www.ncbi.nlm.nih.gov/pubmed/17979153
[52] 
Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - In control of vascular function.  Nature Reviews Molecular Cell Biology 2006; Vol. 7: pp. 359-71.http://www.ncbi.nlm.nih.gov/pubmed/16633338 Internet [cited 2020 Feb 20]
[53] 
Eye.  Fogli S, Del Re M, Rofi E, Posarelli C, Figus M, Danesi R. Clinical pharmacology of intravitreal anti-VEGF drugs.Basingstoke: Nature Publishing Group 2018; 32: pp. 1010-20.
[54] 
Bro T. An eye for an eye? Lack of consensus in off-label use of medications leads to major regional differences in medical costs for the treatment of wet AMD in Sweden. Lakartidningen  2017; 114(48): 2080.
[PMID: 29292948] 
[55] 
DailyMed - MACUGEN- pegaptanib sodium injection, solution https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45d03177-5d52-492c-b2e0-01afc7c8d2e0
[56] 
DailyMed - EYLEA- aflibercept injection, solution https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f96cfd69- da34-41ee-90a9-610a4655cd1c
[57] 
DailyMed - BEOVU- brolucizumab injection, solution https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5d1dc1fa-a2d3-46ed-9e9a-c1a036590d3d
[58] 
Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, et al. Hawk and harrier: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration.Ophthalmology.  Elsevier Inc. 2020; pp. 72-84.
[59] 
DailyMed - LUCENTIS- ranibizumab injection, solution  https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de4e66cc- ca05-4dc9-8262-e00e9b41c36d
[60] 
Nagai N, Ibuki M, Shinoda H, Kameyama K, Tsubota K, Ozawa Y. Maculopapular rash after intravitreal injection of an antivascular endothelial growth factor, aflibercept, for treating age-related macular degeneration Med 2017.
[http://dx.doi.org/10.1097/MD.0000000000006965] 
[61] 
Rosenwasser GOD. Complications of topical ocular anesthetics.  International Ophthalmology Clinics 1989; Vol. 29: pp. 153-8.http://journals.lww.com/00004397-198902930-00005 Internet [cited 2020 Mar 3]
[62] 
Heier JS, Brown DM, Chong V, et al. VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology  2012; 119(12): 2537-48.
[http://dx.doi.org/10.1016/j.ophtha.2012.09.006] [PMID: 23084240] 
[63] 
Eye.  Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: A review of literature.Basingstoke: Nature Publishing Group 2013; 27: pp. 787-94.
[64] 
Maryam AK, Tafgeh M, Mahmoud M, Pasha A, Ahad S, Khalil GF. Short term effect of intravitreal bevacizumab for diabetic macular edema associated with epiretinal membrane Rom J Ophthalmol  2018; 62(3): 212-6.http://www.ncbi.nlm.nih.gov/pubmed/30505990
[http://dx.doi.org/10.22336/rjo.2018.32] 
[65] 
Kang YK, Park HS, Park DH, Shin JP. Incidence and treatment outcomes of secondary epiretinal membrane following intravitreal injection for diabetic macular edema. Sci Rep  2020; 10(1): 528.
[http://dx.doi.org/10.1038/s41598-020-57509-6] [PMID: 31953511] 
[66] 
Avery RL, Gordon GM. Systemic safety of prolonged monthly anti-vascular endothelial growth factor therapy for diabetic macular edema: A systematic review and meta-analysis JAMA Ophthalmol  2016; 134(1): 21-9.http://www.ncbi.nlm.nih.gov/pubmed/26513684
[http://dx.doi.org/10.1001/jamaophthalmol.2015.4070] 
[67] 
Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med  2004; 351(27): 2805-16.
[http://dx.doi.org/10.1056/NEJMoa042760] [PMID: 15625332] 
[68] 
Ng EWM, Shima DT, Calias P, Cunningham ET Jr, Guyer DR, Adamis AP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov  2006; 5(2): 123-32.
[http://dx.doi.org/10.1038/nrd1955] [PMID: 16518379] 
[69] 
Drug Approval Package: Macugen https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-756_Macugen.cfm
[70] 
Boyer DS, Goldbaum M, Leys AM, Starita C. Effect of pegaptanib sodium 0.3 mg intravitreal injections (Macugen) in intraocular pressure: posthoc analysis from V.I.S.I.O.N. study. Br J Ophthalmol  2014; 98(11): 1543-6.
[http://dx.doi.org/10.1136/bjophthalmol-2013-304075] [PMID: 24997182] 
[71] 
EMA 2020.https://www.ema.europa.eu/en/documents/overview/macugen-epar-summary-public_en.pdf
[72] 
Cilley JC, Barfi K, Benson AB, Mulcahy MF. Bevacizumab in the treatment of colorectal cancer Expert Opin Biol Ther  2007; 7(5): 739-49.http://www.tandfonline.com/doi/full/10.1517/14712598.7.5.739
[http://dx.doi.org/10.1517/14712598.7.5.739] 
[73] 
EMA 2019.https://www.ema.europa.eu/en/documents/product-information/avastin-epar-product-information_en.pdf
[74] 
Oliver J. 済無. J Chem Inf Model 2013; 53(9): 1689-99.https://www.ema.europa.eu/en/documents/scientific-discussion/avastin-epar-scientific-discussion_en.pdf
[75] 
Heier JS, Bressler NM, Avery RL, et al. Comparison of aflibercept, bevacizumab, and ranibizumab for treatment of diabetic macular edema: Extrapolation of data to clinical practice. JAMA Ophthalmol  2016; 134(1): 95-9.
[http://dx.doi.org/10.1001/jamaophthalmol.2015.4110] [PMID: 26512939] 
[76] 
Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med  2015; 372(13): 1193-203.
[http://dx.doi.org/10.1056/NEJMoa1414264] [PMID: 25692915] 
[77] 
Taugourdeau-Raymond S, Rouby F, Default A, Jean-Pastor MJ. Bevacizumab-induced serious side-effects: A review of the French pharmacovigilance database Eur J Clin Pharmacol  2012; 68(7): 1103-7.http://www.ncbi.nlm.nih.gov/pubmed/22349162
[http://dx.doi.org/10.1007/s00228-012-1232-7] 
[78] 
Narayanan R, Kuppermann BD, Jones C, Kirkpatrick P. Ranibizumab. Nat Rev Drug Discov  2006; 5(10): 815-6.
[http://dx.doi.org/10.1038/nrd2157] [PMID: 17078173] 
[79] 
Gardlik R, Fusekova I. Pharmacologic therapy for diabetic retinopathy. Semin Ophthalmol  2015; 30(4): 252-63.
[http://dx.doi.org/10.3109/08820538.2013.859280] [PMID: 24571780] 
[80] 
Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, Berg K, Chakravarthy U, Gerendas BS, et al. Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA)Vol 237, Ophthalmologica S Karger AG.   2017; pp. 185-222.
[81] 
Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology  2011; 118(4): 615-25.
[http://dx.doi.org/10.1016/j.ophtha.2011.01.031] [PMID: 21459215] 
[82] 
Hutton DW, Stein JD, Glassman AR, Bressler NM, Jampol LM, Sun JK. Five-year cost-effectiveness of intravitreous ranibizumab therapy vs panretinal photocoagulation for treating proliferative diabetic retinopathy: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol  2019; 33647: 1-9.http://www.ncbi.nlm.nih.gov/pubmed/31647496 [Internet].
[http://dx.doi.org/10.1001/jamaophthalmol.2019.4284] [PMID: 31647496] 
[83] 
Prünte C, Fajnkuchen F, Mahmood S, et al. Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study. Br J Ophthalmol  2016; 100(6): 787-95.
[http://dx.doi.org/10.1136/bjophthalmol-2015-307249] [PMID: 26453639] 
[84] 
Chen G, Li W, Tzekov R, Jiang F, Mao S, Tong Y. Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema: A meta-analysis of randomized controlled trials. PLoS One  2014; 9(12)e115797
[http://dx.doi.org/10.1371/journal.pone.0115797] [PMID: 25541937] 
[85] 
Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA  2002; 99(17): 11393-8.
[http://dx.doi.org/10.1073/pnas.172398299] [PMID: 12177445] 
[86] 
Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci  2005; 46(2): 726-33.
[http://dx.doi.org/10.1167/iovs.04-0601] [PMID: 15671306] 
[87] 
Rakic JM, Lambert V, Devy L, et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci  2003; 44(7): 3186-93.
[http://dx.doi.org/10.1167/iovs.02-1092] [PMID: 12824270] 
[88] 
Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis  2012; 15(2): 171-85.
[http://dx.doi.org/10.1007/s10456-011-9249-6] [PMID: 22302382] 
[89] 
Park SJ, Choi Y, Na YM, et al. Intraocular pharmacokinetics of intravitreal aflibercept (Eylea) in a rabbit model. Invest Ophthalmol Vis Sci  2016; 57(6): 2612-7.
[http://dx.doi.org/10.1167/iovs.16-19204] [PMID: 27258433] 
[90] 
Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology  2016; 123(6): 1351-9.
[http://dx.doi.org/10.1016/j.ophtha.2016.02.022] [PMID: 26935357] 
[91] 
Bressler NM, Beaulieu WT, Maguire MG, Glassman AR, Blinder KJ, Bressler SB, et al. Early response to anti–vascular endothelial growth factor and two-year outcomes among eyes with diabetic macular edema in protocol t Am J Ophthalmol  2018; 195(93): 100.http://www.ncbi.nlm.nih.gov/pubmed/30077569
[92] 
Lang GE, Berta A, Eldem BM, et al. Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: Interim analysis of the RESTORE extension study. Ophthalmology  2013; 120(10): 2004-12.
[http://dx.doi.org/10.1016/j.ophtha.2013.02.019] [PMID: 23725735] 
[93] 
Schmidt-Erfurth U, Lang GE, Holz FG, Schlingemann RO, Lanzetta P, Massin P, et al. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study Ophthalmology  2014; 121(5): 1045-53.http://www.ncbi.nlm.nih.gov/pubmed/24491642
[94] 
Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12- month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care  2010; 33(11): 2399-405.
[http://dx.doi.org/10.2337/dc10-0493] [PMID: 20980427] 
[95] 
Solomon SD, Lindsley KB, Krzystolik MG, Vedula SS, Hawkins BS. Intravitreal bevacizumab versus ranibizumab for treatment of neovascular age-related macular degeneration: findings from a cochrane systematic review Ophthalmology  2016; 123(1): 70-7.http://www.ncbi.nlm.nih.gov/pubmed/26477843
[96] 
https://www.ema.europa.eu/en/documents/product-information/beovu-epar-product-information_en.pdf
[97] 
Holz FG, Dugel PU, Weissgerber G, Hamilton R, Silva R, Bandello F, et al. Single-chain antibody fragment VEGF inhibitor RTH258 for neovascular age-related macular degeneration: a randomized controlled study Ophthalmology  2016; 123(5): 1080-9.http://www.ncbi.nlm.nih.gov/pubmed/26906165
[98] 
Nimz EL, et al. Intraocular and systemic pharmacokinetics of brolucizumab (RTH258) in nonhuman primatesMeeting TA for R in V and O (ARVO) annual, editor.  2016.
[99] 
A study of the efficacy and safety of brolucizumab vs aflibercept in patients with visual impairment due to diabetic macular edema - full text view - clinicaltrials.gov https://clinicaltrials.gov/ct2/show/NCT03481660
[100] 
Study of efficacy and safety of brolucizumab vs. aflibercept in patients with visual impairment due to diabetic macular edema - full text view - clinicaltrials.gov https://clinicaltrials.gov/ct2/show/NCT03481634
[101] 
Markham A. Brolucizumab: First Approval. Drugs  2019; 79(18): 1997-2000.
[http://dx.doi.org/10.1007/s40265-019-01231-9] [PMID: 31768932] 
[102] 
Regula JT, Lundh von Leithner P, Foxton R, et al. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med  2016; 8(11): 1265-88.
[http://dx.doi.org/10.15252/emmm.201505889] [PMID: 27742718] 
[103] 
Klein C, Schaefer W, Regula JT, Dumontet C, Brinkmann U, Bacac M, et al. Engineering therapeutic bispecific antibodies using CrossMab technology Vol 154, Methods Academic Press Inc  2019; 21-31.http://www.ncbi.nlm.nih.gov/pubmed/30453028
[104] 
Sahni J, Patel SS, Dugel PU, Khanani AM, Jhaveri CD, Wykoff CC, et al.  Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial Ophthalmology  2019; 126(8): 1155-70.
[105] 
KG C.. Csaky KG. Data supporting the sustained efficacy o; Oct. 11-15; San Francisco.; a bispecific antibody neutralizing both angiopoiet 2019.https://www.healio.com/ophthalmology/retina-vitreous/news/online/%7Bc50ec9ef-2d84-4c52-9aaa-4193cec0161f%7D/faricimab-demonstrates- durable-ang-2-vegf-suppression
[106] 
A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE) https://clinicaltrials.gov/ct2/show/NCT03622580
[107] 
Sharma A, Kumar N, Kuppermann BD, Bandello F, Loewenstein A. Faricimab: Expanding horizon beyond VEGF. Eye (Lond)  2019; 10–2 [Internet].
[http://dx.doi.org/10.1038/s41433-019-0670-1] [PMID: 31695160] 
[108] 
KG C. HEALIO https://www.healio.com/ophthalmology/retina-vitreous/news/online/%7Bc50ec9ef-2d84-4c52-9aaa-4193cec0161f%7D/faricimab-demonstrates- durable-ang-2-vegf-suppression
[109] 
Cai S, Yang Q, Li X, Zhang Y. The efficacy and safety of aflibercept and conbercept in diabetic macular edemaVol 12, Drug Design, Development and Therapy.  Dove Medical Press Ltd. 2018; pp. 3471-83.
[http://dx.doi.org/10.2147/DDDT.S177192] 
[110] 
Zhang M, Zhang J, Yan M, Li H, Yang C, Yu D. Recombinant anti-vascular endothelial growth factor fusion protein efficiently suppresses choridal neovasularization in monkeys. Mol Vis  2008; 14: 37-49.
[PMID: 18246030] 
[111] 
Suto K, Yamazaki Y, Morita T, Mizuno H. Crystal structures of novel vascular endothelial growth factors (VEGF) from snake venoms: insight into selective VEGF binding to kinase insert domain- containing receptor but not to fms-like tyrosine kinase-1. J Biol Chem  2005; 280(3): 2126-31.
[http://dx.doi.org/10.1074/jbc.M411395200] [PMID: 15542594] 
[112] 
Zhang M, Yu D, Yang C, et al. The pharmacology study of a new recombinant human VEGF receptor-fc fusion protein on experimental choroidal neovascularization. Pharm Res  2009; 26(1): 204-10.
[http://dx.doi.org/10.1007/s11095-008-9718-9] [PMID: 18854954] 
[113] 
Li H, Lei N, Zhang M, Li Y, Xiao H, Hao X. Pharmacokinetics of a long-lasting anti-VEGF fusion protein in rabbit. Exp Eye Res  2012; 97(1): 154-9.
[http://dx.doi.org/10.1016/j.exer.2011.09.002] [PMID: 21933673] 
[114] 
Liu K, Song Y, Xu G, et al. PHOENIX study group. Conbercept for treatment of neovascular age-related macular degeneration: results of the randomized phase 3 PHOENIX study. Am J Ophthalmol  2019; 197: 156-67.
[http://dx.doi.org/10.1016/j.ajo.2018.08.026] [PMID: 30148987] 
[115] 
Efficacy and safety trial of conbercept intravitreal injection for neovascular age-related macular degeneration (PANDA-1)  https://clinicaltrials.gov/ct2/show/NCT03577899?term=Conbercept&draw=2&rank=15
[116] 
Efficacy and safety trial of conbercept intravitreal injection for neovascular age-related macular degeneration (PANDA-2) https://clinicaltrials.gov/ct2/show/NCT03630952?term=Conbercept&draw=2&rank=16
[117] 
Ghanchi F, Bailey C, Chakravarthy U, Cohen S, Dodson P, Gibson J, et al. Diabetic retinopathy guidelines working group. the royal college of ophthalmologists’ clinical guidelines for diabetic retinopathy: a summary. Eye (Lond)  2013; 27(2): 285-7.
[http://dx.doi.org/10.1038/eye.2012.287] [PMID: 23306724] 
[118] 
Romero-Aroca P, Reyes-Torres J, Baget-Bernaldiz M, Blasco- Suñe C. Laser treatment for diabetic macular edema in the 21st century. Curr Diabetes Rev  2014; 10(2): 100-12.
[http://dx.doi.org/10.2174/1573399810666140402123026] [PMID: 24852439] 
[119] 
Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology  2012; 119(4): 789-801.http://www.ncbi.nlm.nih.gov/pubmed/22330964
[120] 
Gross JG, Glassman AR, Jampol LM, et al. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: A randomized clinical trial. JAMA -. JAMA  2015; 314(20): 2137-46.
[http://dx.doi.org/10.1001/jama.2015.15217] [PMID: 26565927] 
[121] 
Jorge ECEN, Jorge EN, Botelho M, Farat JG, Virgili G, El Dib R. Monotherapy laser photocoagulation for diabetic macular oedema. Cochrane Database Syst Rev  2018; 10(10)CD010859
[http://dx.doi.org/10.1002/14651858.CD010859.pub2] [PMID: 30320466] 
[122] 
Figueira J, Khan J, Nunes S, Sivaprasad S, Rosa A, de Abreu JF, et al. Prospective randomised controlled trial comparing sub-threshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular oedema Br J Ophthalmol  2009; 93(10): 1341-4.http://www.ncbi.nlm.nih.gov/pubmed/19054831
[http://dx.doi.org/10.1136/bjo.2008.146712] 
[123] 
Chhablani J, Alshareef R, Kim DT, Narayanan R, Goud A, Mathai A. Comparison of different settings for yellow subthreshold laser treatment in diabetic macular edema. BMC Ophthalmol  2018; 18(1): 168.
[http://dx.doi.org/10.1186/s12886-018-0841-z] [PMID: 29996798] 
[124] 
Lattanzio R, Cicinelli MV, Bandello F. Intravitreal Steroids in Diabetic Macular Edema. Dev Ophthalmol  2017; 60: 78-90.
[http://dx.doi.org/10.1159/000459691] [PMID: 28427068] 
[125] 
González-Mariscal L, Betanzos A, Nava P, Jaramillo BE. Tight junction proteins. Prog Biophys Mol Biol  2003; 81(1): 1-44.
[http://dx.doi.org/10.1016/S0079-6107(02)00037-8] [PMID: 12475568] 
[126] 
White NH, Sun W, Cleary PA, Tamborlane WV, Danis RP, Hainsworth DP, et al. Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: Comparison of adults and adolescents Diabetes  2010; 59(5): 1244-53.http://www.ncbi.nlm.nih.gov/pubmed/20150283
[127] 
Zhang X, Zeng H, Bao S, Wang N, Gillies MC. Diabetic macular edema: new concepts in patho-physiology and treatment Cell Biosci  2014; 4(1): 27.http://www.ncbi.nlm.nih.gov/pubmed/24955234
[http://dx.doi.org/10.1186/2045-3701-4-27] 
[128] 
Diabetic Retinopathy Clinical Research Network, Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, et al. A Phase II Randomized Clinical Trial of Intravitreal Bevacizumab for Diabetic Macular Edema Ophthalmology  2007; 114(10): 1860-7.http://www.ncbi.nlm.nih.gov/pubmed/17698196
[129] 
Sohn HJ, Han DH, Kim IT, Oh IK, Kim KH, Lee DY, et al. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema Am J Ophthalmol  2011; 152(4): 686-94.http://www.ncbi.nlm.nih.gov/pubmed/21782151
[http://dx.doi.org/10.1016/j.ajo.2011.03.033] 
[130] 
Sakamoto T, Ishibashi T, Ogura Y, Shiraga F, Takeuchi S, Yamashita H, et al. [Survey of triamcinolone-related non-infectious endophthalmitis] Nihon Ganka Gakkai Zasshi  2011; 115(6): 523-8.http://www.ncbi.nlm.nih.gov/pubmed/21735756
[131] 
Quiram PA, Gonzales CR, Schwartz SD. Severe steroid-induced glaucoma following intravitreal injection of triamcinolone acetonide Am J Ophthalmol  2006; 141(3): 580-2.http://www.ncbi.nlm.nih.gov/pubmed/16490518
[http://dx.doi.org/10.1016/j.ajo.2005.10.004] 
[132] 
Pacella F, Ferraresi AF, Turchetti P, Lenzi T, Giustolisi R, Bottone A, et al. Intravitreal injection of ozurdex® implant in patients with persistent diabetic macular edema, with six-month follow-up Ophthalmol Eye Dis 2016.
[133] 
Sarao V, Veritti D, Boscia F, Lanzetta P. Intravitreal steroids for the treatment of retinal diseases ScientificWorldJournal 2014.http://www.ncbi.nlm.nih.gov/pubmed/24526927
[http://dx.doi.org/10.1155/2014/989501] 
[134] 
Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, Glassman AR, et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema Arch Ophthalmol  2009; 127(3): 245-51.http://www.ncbi.nlm.nih.gov/pubmed/19273785
[135] 
Diabetic Retinopathy Clinical Research Network. A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Focal/Grid Photocoagulation for Diabetic Macular Edema Ophthalmology  2008; 115(9): 1149.http://www.ncbi.nlm.nih.gov/pubmed/18662829
[136] 
Pacella F, Romano MR, Turchetti P, et al. An eighteen-month follow-up study on the effects of Intravitreal Dexamethasone Implant in diabetic macular edema refractory to anti-VEGF therapy. Int J Ophthalmol  2016; 9(10): 1427-32.
[PMID: 27803859] 
[137] 
FDA. HIGHLIGHTS OF PRESCRIBING INFORMATION OZURDEX 2014.www.fda.gov/medwatch
[138] 
Maturi RK, Glassman AR, Liu D, et al. Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: A DRCR network phase 2 randomized clinical trial. JAMA Ophthalmol  2018; 136(1): 29-38.
[http://dx.doi.org/10.1001/jamaophthalmol.2017.4914] [PMID: 29127949] 
[139] 
Callanan DG, Gupta S, Boyer DS, Ciulla TA, Singer MA, Kuppermann BD, et al. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema.  Ophthalmology 2013; pp. 1843-51.http://www.ncbi.nlm.nih.gov/pubmed/23706947 [Internet]
[140] 
Degoumois A, Akesbi J, Laurens C, et al. Efficacité des implants intravitréens de dexaméthasone dans l’œdème maculaire hors occlusions veineuses : résultats sur une cohorte de 80 patients. J Fr Ophtalmol  2015; 38(2): 126-33.
[http://dx.doi.org/10.1016/j.jfo.2014.08.003] [PMID: 25592383] 
[141] 
Boyer DS, Faber D, Gupta S, Patel SS, Tabandeh H, Li XY, et al. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients Retina  2011; 31(5): 915-23.http://www.ncbi.nlm.nih.gov/pubmed/21487341
[http://dx.doi.org/10.1097/IAE.0b013e318206d18c] 
[142] 
Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology  2012; 119(10): 2125-32.
[http://dx.doi.org/10.1016/j.ophtha.2012.04.030] [PMID: 22727177] 
[143] 
Campochiaro PA, Hafiz G, Shah SM, Bloom S, Brown DM, Busquets M, et al. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert Ophthalmology  2010; 117(7): 1393-9.http://www.ncbi.nlm.nih.gov/pubmed/20202684
[http://dx.doi.org/10.1016/j.ophtha.2009.11.024] 
[144] 
Kane FE, Burdan J, Cutino A, Green KE. Iluvien: a new sustained delivery technology for posterior eye disease Expert Opin Drug Deliv  2008; 5(9): 1039-46.https://www.tandfonline.com/doi/full/10.1517/17425247.5.9.1039
[http://dx.doi.org/10.1517/17425247.5.9.1039] 
[145] 
Schwartz SG, Flynn HW Jr. Fluocinolone acetonide implantable device for diabetic retinopathy. Curr Pharm Biotechnol  2011; 12(3): 347-51.
[http://dx.doi.org/10.2174/138920111794480651] [PMID: 20939799] 
[146] 
Kompella UB, Kadam RS, Lee VHL. Recent advances in ophthalmic drug delivery.  Therapeutic Delivery. NIH Public Access 2010; Vol. 1: pp. 435-56.
[147] 
Jonas JB, Söfker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol  2001; 132(3): 425-7.
[http://dx.doi.org/10.1016/S0002-9394(01)01010-8] [PMID: 11530068] 
[148] 
Dyer D, Callanan D, Bochow T, et al. Clinical evaluation of the safety and efficacy of preservative-free triamcinolone (triesence [triamcinolone acetonide injectable suspension] 40 mg/ml) for visualization during pars plana vitrectomy. Retina  2009; 29(1): 38-45.
[http://dx.doi.org/10.1097/IAE.0b013e318188c6e2] [PMID: 18827733] 
[149] 
Lang Y, Leibu R, Shoham N, Miller B, Perlman I. Evaluation of intravitreal kenalog toxicity in humans. Ophthalmology  2007; 114(4): 724-31.
[http://dx.doi.org/10.1016/j.ophtha.2006.08.044] [PMID: 17224183] 
[150] 
Sonoda S, Sakamoto T, Yamashita T, et al. Effect of intravitreal triamcinolone acetonide or bevacizumab on choroidal thickness in eyes with diabetic macular edema. Invest Ophthalmol Vis Sci  2014; 55(6): 3979-85.
[http://dx.doi.org/10.1167/iovs.14-14188] [PMID: 24906857] 
[151] 
Bandello F, Polito A, Pognuz DR, Monaco P, Dimastrogiovanni A, Paissios J. Triamcinolone as adjunctive treatment to laser panretinal photocoagulation for proliferative diabetic retinopathy Arch Ophthalmol  2006; 124(5): 643-50.http://www.ncbi.nlm.nih.gov/pubmed/16682585
[http://dx.doi.org/10.1001/archopht.124.5.643] 
[152] 
Kohly RP, Muni RH, Kertes PJ. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular EDEMA.  Evidence-Based Ophthalmology 2010; Vol. 11: pp. 199-201.
[153] 
Beer PM, Bakri SJ, Singh RJ, Liu W, Peters GB III, Miller M. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology  2003; 110(4): 681-6.
[http://dx.doi.org/10.1016/S0161-6420(02)01969-3] [PMID: 12689886] 
[154] 
Feldman-Billard S, Chibani A, Héron E. Intravitreal Triamcinolone and Blood GlucoseVol 115, Ophthalmology.   Elsevier Inc. 2008; pp. 917-7.
[http://dx.doi.org/10.1016/j.ophtha.2007.11.012] 
[155] 
Fukushima H, Kato S, Kaiya T, Yuguchi T, Ohara K, Noma H, et al. Effect of subconjunctival steroid injection on intraocular inflammation and blood glucose level after cataract surgery in diabetic patients J Cataract Refract Surg  2001; 27(9): 1386-91. http://journals.lww.com/10.1016/S0886-3350(01)00783-0
[156] 
Do DV, Nguyen QD, Boyer D, Schmidt-Erfurth U, Brown DM, Vitti R, et al. One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema Ophthalmology [Internet] 2012 Aug [cited 2020 Feb 20];119(8):1658–65  2012; 119(8): 1658-65.http://www.ncbi.nlm.nih.gov/pubmed/22537617
[http://dx.doi.org/10.1016/j.ophtha.2012.02.010] 
[157] 
Nepomuceno AB, Takaki E, Paes de Almeida FP, Peroni R, Cardillo JA, Siqueira RC, et al. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema Am J Ophthalmol  2013; 156(3): 502-10.http://www.ncbi.nlm.nih.gov/pubmed/23795985
[http://dx.doi.org/10.1016/j.ajo.2013.04.026] 
[158] 
Solaiman KAM, Diab MM, Dabour SA. Repeated intravitreal bevacizumab injection with and without macular grid photocoagulation for treatment of diffuse diabetic macular edema Retina  2013; 33(8): 1623-9.http://www.ncbi.nlm.nih.gov/pubmed/23538584
[http://dx.doi.org/10.1097/IAE.0b013e318285c99d] 
[159] 
Heng LZ, Sivaprasad S, Crosby-Nwaobi R, et al. A prospective randomised controlled clinical trial comparing a combination of repeated intravitreal Ozurdex and macular laser therapy versus macular laser only in centre-involving diabetic macular oedema (OZLASE study). Br J Ophthalmol  2016; 100(6): 802-7.
[http://dx.doi.org/10.1136/bjophthalmol-2015-307136] [PMID: 26472406] 
[160] 
Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev  2017; 2(2)MR000033
[PMID: 28207928] 
[161] 
Lexchin J. Sponsorship bias in clinical research. Int J Risk Saf Med  2012; 24(4): 233-42.
[http://dx.doi.org/10.3233/JRS-2012-0574] [PMID: 23135338] 
[162] 
Naci H, Dias S, Ades AE. Industry sponsorship bias in research findings: a network meta-analysis of LDL cholesterol reduction in randomised trials of statins. BMJ  2014; 349: g5741.
[http://dx.doi.org/10.1136/bmj.g5741] [PMID: 25281681] 
[163] 
	Study of PAN-90806 Eye Drops, Suspension for Neovascular AMD https://clinicaltrials.gov/ct2/show/NCT03479372
Rights & Permissions Print Cite
Article Metrics
66
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/1574886315666200902154322	Print ISSN 1574-8863
Publisher Name Bentham Science Publisher	Online ISSN 2212-3911
Current Drug Safety

Biologic Therapy and Treatment Options in Diabetic Retinopathy with Diabetic Macular Edema

Abstract

Related Journals

Related Books

Related Articles
